Why the study?
Bioresorbable scaffolds offer a novel treatment for coronary artery disease with potential advantages over metallic drug-eluting stents, but their clinical status and degradation processes require comprehensive review.
Answers are grounded in this paper and cite their sources.
Bioresorbable scaffolds represent a novel approach in the treatment of coronary artery disease which allows for vessel wall support without leaving a permanent foreign body in the coronary artery. This technology has the potential to reduce some of the shortcomings of current standard treatment with metallic drug-eluting stents, such as late in-stent restenosis, impaired vasomotion of the stented segment and hindrance of surgical revascularizations. Currently, several bioresorbable scaffolds are available and undergoing clinical or preclinical evaluation. This review will present the current status of development of bioresorbable scaffolds, describe the degradation/resorption process of each device and the clinical data available to date.
No takes yet. Share an insight, caveat, or question.
Kraak et al. (2014) studied Healthy (n=30). WE43 magnesium alloy vs. Nickel-titanium alloy (NiTi) and control was evaluated on In vivo degradation and inflammatory response.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: